Investigating the Optimal Use of Novel Immunotherapies for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Investigating the Optimal Use of Novel Immunotherapies for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma is organized by Pharmacy Times Continuing Education (PTCE),Release date: November 8, 2022,Expiration date: November 8, 2023.,Description:,Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma that accounts for 25% to 45% of new lymphoma cases annually, with 30% to 40% of patients having disease that is relapsed or refractory (R/R). R-CHOP, consisting of rituximab, an anti-CD20 antibody, along with cyclophosphamide, doxorubicin, prednisone, and vincristine, has become the standard treatment regimen due to overall improvement of outcomes. Alternative treatments, such as salvage chemotherapy followed by high-dose chemotherapy and autologous stem-cell transplantation, result in many patients experiencing relapsed disease. New and emerging therapies, including chimeric antigen receptor T-cell therapies, antibody-drug conjugates, and bispecific antibodies, have shown promise in improving patient outcomes. Pharmacists must consider various aspects of new therapies for R/R DLBCL when determining how to implement these strategies into existing clinical pathways. Pharmacists will be able to use the data presented in clinical practice as they help patients navigate traditional and emerging new therapies in the treatment of R/R DLBCL.,Educational Objectives:,At the completion of this activity, participants will be able to:,Analyze the data investigating new and emerging novel immunotherapies in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL),Apply emerging clinical data of novel immunotherapies into treatment pathways for relapsed/refractory DLBCL,Differentiate roles of oncology care providers in overcoming various challenges to the use of novel immunotherapies in the treatment of DLBCL,Identify the unique role of oncology pharmacists in overcoming various challenges to the use of novel immunotherapies in the treatment of DLBCL